RCN Pareto Strategic Allocation ETF (PRTO)

Proteon Therapeutics, Inc. (PRTO) is a biopharmaceutical company that focuses on the development of novel therapeutic products for patients with kidney and vascular diseases. The company's lead product candidate, vonapanitase, is a recombinant human elastase that has the potential to improve vascular access outcomes in patients with end-stage renal disease requiring hemodialysis. Vonapanitase is currently being evaluated in Phase 3 clinical trials.

In addition to vonapanitase, Proteon is also developing other product candidates for the treatment of kidney and vascular diseases, including an inhibitor of complement factor B and a synthetic small molecule that activates the Tie2 receptor.